Abstract: A system and related methods are provided for processing a diagnostic test article, for example, one that is used for medical or substance testing. The system and methods combine a diagnostic test article with a software application that is integrated with each of a mobile communication device and a cloud-based network via an internet connection for achieving certain advantages and improvements over conventional point of use diagnostics.

Abstract: A specimen sample collection device is disclosed, the device including: a base having a neck extending therefrom, a film-puncture element disposed within the neck, and one or more fluid ports extending through the base within the neck; a cap engaged with the neck, the cap comprising a film attached about an inner cylinder of the cap along a periphery thereof; wherein the film defines a buffer-containing cavity within the cap, and wherein the buffer-containing cavity is configured to hold a preservation buffer for preserving a sample stored within a collection reservoir of the device.

Abstract: A system and related methods are provided for processing a diagnostic test article, for example, one that is used for medical or substance testing. The system and methods combine a diagnostic test article with a software application that is integrated with each of a mobile communication device and a cloud-based network via an internet connection for achieving certain advantages and improvements over conventional point of use diagnostics.

Abstract: This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.

Abstract: Provided herein are genetic markers for predicting response to antipsychotic treatment. Genotyping of the disclosed SNPs can be used to predict response to antipsychotic drugs in patients suffering from schizophrenia. There is provided method of treating a subject with an antipsychotic medication comprising obtaining genetic information from the subject comprising the sequence of SNPs rs6923761, rs2300615, and rs1042044 to provide the GLP1 R Antipsychotic Response Phenotype (GARP) genetic signature of the subject; and administering an antipsychotic medication to the subject based on the GARP genetic signature of the subject.

Abstract: Methods for the chiral separation and quantitative determination of the d- and l-enantiomers for amphetamine and methamphetamine in bodily fluids and tissues are provided. The method comprises providing a bodily fluid or tissue sample from a subject, extracting target analyte(s) from the sample, followed by eluting on a liquid chromatography column comprising a chiral stationary phase to yield an eluent, which is then analyzed for the presence of the analytes using a mass analyzer.

Abstract: Methods for determining the presence and level of active drugs in fluid samples are provided. Advantageously, entire families or classes of drugs can be tested for in one test by identifying the enzyme or receptor upon which members of that drug family act and measuring enzyme activity levels or binding activity levels of receptors. Methods for establishing standard activity levels of these drugs based upon results from samples having known quantities of drug therein are also provided.

Abstract: Methods for determining chronic hepatitis C infection are provided by the present invention. The methods generally involve determining the optical density of fluid samples which have tested positive for hepatitis C infection using an antibody-based assay. The optical density can then be used to determine in a predictive or probability-based manner whether the fluid sample contains chronic hepatitis C infection or whether the fluid sample merely contains antibodies to hepatitis C infection without resorting to costly molecular detection methods. Thus, the present invention permits differentiation between individuals who have cleared hepatitis C infection but still test positive in an antibody-based assay from individuals having chronic hepatitis C infection.

Abstract: Methods for determining the presence and level of active drugs in fluid samples are provided. Advantageously, entire families or classes of drugs can be tested for in one test by identifying the enzyme or receptor upon which members of that drug family act and measuring enzyme activity levels or binding activity levels of receptors. Methods for establishing standard activity levels of these drugs based upon results from samples having known quantities of drug therein are also provided.

Abstract: Methods for determining the presence and level of active drugs in fluid samples are provided. Advantageously, entire families or classes of drugs can be tested for in one test by identifying the enzyme or receptor upon which members of that drug family act and measuring enzyme activity levels or binding activity levels of receptors. Methods for establishing standard activity levels of these drugs based upon results from samples having known quantities of drug therein are also provided.

Abstract: A method is described for the production of large quantities of biologic which serves as an immunomodulator and also to decrease the concentration of serum cholesterol and triglycerides. In practice, an animal such as a goat is injected with a virus (preferably a normally immunosuppressive Parvovirus) and allowed to react to the virus for a period of time to generate the biologic in its blood serum; blood is then withdrawn from the animal and the serum fraction thereof, containing the desired biologic, can be used in fractionated or more highly purified form. Examples are also provided of use of the biologic as an immunostimulant and for reducing serum cholesterol and triglycerides.

Abstract: A method is described for the production of large quantities of biologic which serves as an immunomodulator and also to decrease the concentration of serum cholesterol and triglycerides. In practice, an animal such as a goat is injected with a virus (preferably a normally immunosuppressive Parvovirus) and allowed to react to the virus for a period of time to generate the biologic in its blood serum; blood is then withdrawn from the animal and the serum fraction thereof, containing the desired biologic, can be used in fractionated or more highly purified form. Examples are also provided of use of the biologic as an immunostimulant and for reducing serum cholesterol and triglycerides.